2022 Boehringer Ingelheim Innovation Prize and Spring Networking Reception

Thursday, April 28th, 2022 starting at 4:45 pm at Lab Central, 700 Main Street, Cambridge, MA 02139

We’re excited to welcome you back to an ‘In Person’ event where together we can celebrate innovation with our 2022 Boston Innovation Prize and discuss a key topic of interest in our Boehringer Ingelheim Academy session. We look forward to joining you for an evening of celebration, discussion, and networking!

Boehringer Ingelheim's Grass Root Innovation Program

Boehringer Ingelheim's Innovation Prize

Boston Innovation Prize, 2022

Boehringer Ingelheim recognizes the impact biotech start-ups can have to create and sustain innovative pipelines for the pharma industry. These entrepreneurial scientists are driven by their passion to innovate and create new medicines for patients. We know that passion. And our entrepreneurial heritage, from our roots in a small factory in 1885 to today’s multi-billion-dollar global organization, has taught us the importance of nurturing young science and technology businesses.

The innovation power of young life-science companies and bio-entrepreneurs is an essential element for the discovery of the next generation of breakthrough medicines. Our Innovation Prize recognizes the challenge and dedication it takes to start a new company by supporting the innovation process and celebrating life-science entrepreneurs.

The BI Innovation Prize (valued at $75,000), which provides access to lab space and shared equipment at the biotech incubator LabCentral 's 700 Main Street facility will be awarded live during the event. To apply, see the bottom of this announcement. Qualified applicants will be invited to present at the poster session, which is open to the public and takes place at Lab Central, Cambridge, MA. Of the presented posters, our audience will choose five companies for a final, oral pitch session and a panel of judges will award the prize to the winner.

Past winners have consistently told us the best benefit of winning the prize is the network connections they form during the process. Selected previous winners include Thymmune Therapeutics, Synthis Therapeutics, Abexxa Biologics (acquired by BI in 2021), RIFT Biotherapeutics, and Axonis.

Entry Requirements

We invite all inventors, early-stage innovators and spin-outs, that are pursuing life-science therapeutic platform technologies and therapeutics (in any indication, any modality), to participate.

Inclusion/exclusion criteria

• Companies must be founded and have their principal place of business in New England
• Companies cannot be capitalized over $2 million
• Companies must not have a major partnership with another large bio-pharmaceutical company
• Companies must be focused on new target concepts or drug discovery in any therapeutic indication. Please note that CROs, diagnostics, instrument development, and health-IT are excluded.

How to apply

Applicants must provide a non-confidential deck of no more than seven slides, which will be used for the 5-minute pitch if successful. Slides must address unmet medical need, solution, scientific principal, key data supporting the scientific principal, overview of business case, and intellectual property.

SUBMISSION DEADLINE: BY END OF BUSINESS, MONDAY MARCH 28TH, 2022

Please send your application: [email protected]

Boehringer Ingelheim Academy: “Pharma Partnering in the New Normal”

Over the last two years, we have witnessed the incredible achievements of industry and academic collaboration and been inspired by the power of science and partnership to transform lives and society, showing that a global pandemic is no barrier to innovation.

In our first ‘in person’ BI Academy session since early 2020, we will be reflecting on the experiences of the last couple of years and how flexibility, agility and resilience have enabled us to adopt new ways of working and continue to support breakthrough science and the innovators that are making that happen.

As we emerge into our ‘New Normal’ we look forward to discussing how these unprecedented circumstances have shaped our partnering experiences. How do small companies reach out to funders and prospective partners in this more remote-friendly era. We will discuss what we have learned so far, and how we will chart our path forward to safeguard partnership in innovation and the next generation of transformational therapies for patients.

Moderator: Scott DeWire, US Head of BD&L, BI

Panelists:

• Fei Shen, US Head BI Venture Fund
• Junjun Gao, Research Beyond Borders at BI
• Jon Violin, CEO and Founder, Veridian Bio
• Priyanka Rhogati, Venture Partner, Longwood Fund

Boehringer Ingelheim's Academy

EVENING AGENDA

4:45 pm - 5:15pm :: Arrival and Registration

5:15 pm - 6:00pm :: Networking Reception

6:00 pm - 7:00pm :: BI Academy Panel

7:00 pm - 7:15pm :: Announce top 5 of Innovation Prize Finalists

7:15 pm - 8:00 pm :: Pitch Presentations

8:00 pm - 8:15pm :: Judging for Grand Prize

8:15 pm - 8:30 pm :: Innovation Prize Award

ALL ENTRY PRESENTATIONS (INNOVATION PRIZE) MUST BE SUBMITTED BY END OF BUSINESS, MONDAY MARCH 28TH, 2022.

ALL ATTENDEES MUST BE REGISTERED VIA EVENTBRITE TO ENTER FOR THE PRIZE.

Please send your application: [email protected]

Good luck – and we look forward to seeing you in Boston!

NB:  All attendees of the Boehringer Ingelheim Innovation Prize event will be required to confirm proof of full vaccination with LabCentral Event Manager(s).

Host or Publisher Boehringer Ingelheim Pharmaceuticals